{
  "docId": "019de073-a45e-764e-97a1-b4793295a3f1",
  "docSlug": "90578b12d3108983c23425e7ddd95d83",
  "documentTitle": "ATAI | Investor Presentation Deck | 41 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 41,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 18,
  "notes": "The chart compares 25mg, 10mg, and 1mg (comparator) dosages. Statistical significance is marked with asterisks.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a45e-764e-97a1-b4793295a3f1/20",
  "deckHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1",
  "deckJsonHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1.json",
  "deckAnchorHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.27,
        "x": 0.49,
        "y": 0.28
      },
      "kind": "callout",
      "text": "Primary endpoint Week 3 : 25mg Diff = -6.6, p value = <0.001 vs 1mg 10mg Diff = -2.5, p value = 0.184",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a67e5df8-8394-474a-a55e-cadb3a70a5c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.78,
        "x": 0.12,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Line chart showing MADRS score changes over time for 25mg, 10mg, and 1mg dosages.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92c152d6-116a-4088-b975-873a0557ff7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.2,
        "x": 0.67,
        "y": 0.625
      },
      "kind": "legend",
      "text": "* = statistically significant treatment difference vs 1mg at visit",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "742e3c79-260d-4424-9169-9cb2c16615a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "subtitle",
      "text": "Source: Schedule 13D filed with the SEC as of November 29th, 2021. Note: MADRS = Montgomery-Åsberg Depression Rating Scale;; COMP360 = a proprietary high-purity, polymorphic crystalline formulation of psilocybin; In COMPASS's model of psilocybin therapy, COMP360 is administered in conjunction with psychological support from specially trained therapists. 1. Ownership percentage as of June 30th, 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc00dc84-d718-439e-b291-585eccd115a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "COMP360 Phase 2b trial showed a rapid, sustained reduction in depressive symptoms in 233 patients with TRD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1649d91d-762c-409b-9c71-7bce62341d73",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 41,
      "from": 6,
      "beatId": "54d980bb-d331-41ca-8841-b0eb7beb049c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation provides a solution by showcasing ATAI Life Sciences' pipeline and progress in developing treatments for mental health disorders.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 40,
      "from": 10,
      "beatId": "4c06d6d1-b3e1-4c1e-bceb-806b8f57a880",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The presentation provides evidence and proof of the effectiveness of ATAI Life Sciences' treatments through various studies and data.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 40,
      "from": 10,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "5cd92045-52c0-4b53-b15d-4dd6b345ff72",
      "evidence": "The presentation showcases ATAI Life Sciences' pipeline and progress in developing treatments for mental health disorders.",
      "position": 1,
      "objective": "How can we effectively treat mental health disorders?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}